Tam S, Yao CMK, Amit M, et al. - In the present study, the researchers determined the risks for mortality in patients with cutaneous squamous cell carcinoma (cSCC) and immunosuppression vs nonimmunosuppression and contrasted the difference in mortality risk based on the cause of immunocompromise. From January 1, 1995, to September 30, 2015, patients who had no treatment, wide local excision, or biopsy of the lesions were eligible for inclusion. According to their immune status (immunosuppression vs no immunosuppression), candidates were divided into two groups. Seven hundred ninety-six patients (680 men [85.4%]; median age, 69 [range, 27-98] years) with cSCC were involved. According to this retrospective cohort study, immunosuppression was independently related to a worse outcome in cSCC, with a 2.32 times raised the risk of disease-specific death after adjusting for age, history of skin cancer, recurrent or persistent disease status, disease stage, and treatment.